Article

Effects of tumor mutation burden on the antigen presentation pathway

2021-04-14

Abstract excerpt

Tumor mutation burden (TMB) is used to select patients to receive immune checkpoint inhibitors (ICIs) but has mixed predictive capabilities. We hypothesized that inactivation of antigen presenting genes (APGs) that result from increased TMBs would result in inherent resistance to ICIs. We observed that somatic mutations in APGs were associated with increasing TMBs across 9,418 tumor samples of 33 different histolo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9c8193cd-9566-50a8-9ae7-1183e6623e0f
DOI: 10.1101/2021.04.14.439829

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effects of tumor mutation burden on the antigen presentation pathwayDOI 10.1101/2021.04.14.439829Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read

Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.Semantic proximity Read

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read

Correlate tumor mutation burden with immune signatures in human cancersSemantic proximity Read

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.Semantic proximity Read

Mutation-Derived Neoantigens for Cancer ImmunotherapySemantic proximity Read